{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021847","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.471725+00:00","generated_at":"2026-06-22T07:49:52.638110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cytokinetics Q3 net loss $142.3M, cash $896M; FDA AdCom Dec 13 for omecamtiv mecarbil","bullets":["Net loss of $142.3M ($1.52/share) vs $76.1M ($0.95) in Q3 2021; revenue $2.5M, down from $5.4M.","Cash, equivalents and investments $896.2M; net proceeds of $523.6M from 3.50% convertible notes due 2027.","FDA Advisory Committee to review omecamtiv mecarbil NDA on Dec 13, 2022; PDUFA target Feb 28, 2023.","SEQUOIA-HCM (aficamten Phase 3) enrollment ongoing; results expected in 2H 2023.","COURAGE-ALS (reldesemtiv Phase 3) continues after first interim analysis; enrollment to complete 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021847","json":"https://secwatch.observer/filing/0000950170-22-021847.json","markdown":"https://secwatch.observer/filing/0000950170-22-021847.md","text":"https://secwatch.observer/filing/0000950170-22-021847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/0000950170-22-021847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/cytk-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T07:49:52.638110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"003f284c80d5bb8ba3569859f224842bbd27ddd9","claim":"CYTOKINETICS INC reported third quarter of 2022 results: net income Net loss for the third quarter was $142.3 million, EPS $1.52 per share.","evidence_excerpt":"Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the third quarter of 2022. Net loss for the third quarter was $142.3 million, or $1.52 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1061983/000095017022021847/0000950170-22-021847-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2022"},{"label":"Net income","value":"Net loss for the third quarter was $142.3 million"},{"label":"EPS","value":"$1.52 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}